New York University Cancer Institute is now a member of the Worldwide Innovative Network (WIN) in personalized cancer medicine Consortium. NYU Cancer Institute, which has been an NCI-designated Comprehensive Cancer Center for more than 33 years, aims to play a role in WIN’s efforts to translate new approaches in personalized cancer medicine into patient care worldwide.
The WIN Consortium is a global network of 29 academic, pharmaceutical, biotech, healthcare IT, and patient advocacy organizations aiming to accelerate the pace and reduce the cost of translating promising advances in genomic-based cancer research into the standard of patient care worldwide. Founded in 2010, it was created to spur collaboration between all stakeholders in personalized cancer medicine and to carry out cross-sector, worldwide clinical trials through the Consortium’s network of academic and industry partners. WIN is a nongovernmental, not-for-profit organization headquartered in Paris.
“NYU Cancer Institute joining WIN is an important step in the continued development of the Consortium’s capabilities and potential,” stated WIN Consortium chairman John Mendelsohn, M.D. “The clear strengths NYU brings—experience serving a diverse patient population, excellence in disease-focused and basic science research, and committed, involved leadership—will help speed the translation of personalized cancer medicine innovations into the treatment of cancer patients.”
NYU Cancer Institute isn’t the only organization teaming up toward an epic WIN for personalized cancer medicine. Pfizer joined the WIN Consortium in December, Oracle Health Sciences joined in October, and other members include Agilent Technologies, GE Healthcare, Foundation Medicine, and Life Technologies.